Romanian Anti-TB Drugs resistance surveillance 2003-2004
Ioan Paul Stoicescu1, Daniela Homorodean2,Domnica Chiotan1, Olga Moldovan1, Daniela Diculencu3, Cristian Popa1, Anca Macri1, Iuliana Husar1, Lucica Diţiu4, Mohamed Abdel Aziz4, Sven Hoffner5
1"Marius Nasta" Institute of Pneumology - Bucharest, Romania2 "Leon Daniello" Hospital of Pneumology - Cluj Napoca, Romania3 Hospital of Pneumology Iasi, Romania4 WHO5 Swedish Institute for Infectious Disease Control - Stockholm, Sweden
Contact: stoicescup@yahoo.com
Romania decided and initiated a DRS for anti-TB drugs at national level using the standardized methodology proposed by WHO and IUATLD.
The DRS protocol was designed with technical assistance from WHO; the surveillance started in June 2003 and ended in June 2004.
It was tested the susceptibility to the 4 first line anti-TB drugs: Isoniazide (H), Rifampicine (R), Streptomycine (S), Ethambutol (E).
Drug susceptibility testing used: indirect absolute concentration method.
There were included in the survey 1251 TB patients from the 60 clusters: 869 new cases and 382 previously treated. From the
penitentiary system were included 85 TB patients, 47 new cases and 38 previously treated.
Results:
General population: New cases Previously treated
- any resistance 14.3 % 32.7 %
- monoresistance 8.9 % 12.6 %
- MDR (H+R) 2.9 % 11.0 %
- H+E and/or S 1.8 % 9.2 %
- R+E and/or S 0.4 % 0.0 %
Penitentiary system:
- any resistance 17.0 % 42.1 %
- monoresistance H 6.0% 7.9 %
- monoresistance R 6.4 % 7.8 %
- MDR 4.3 % 13.2 %
Estimations of the trend of anti-TB drug resistance in Romania for the next period was proposed.
